Australian biopharmaceutical company Dimerix Limited is currently developing DMX-200 for respiratory complications in COVID-19 patients with two ongoing Phase 3 clinical trials. The drug is also undergoing a Phase 3 clinical trial for focal segmental glomerulosclerosis disease. Additionally, Dimerix is in the pre-clinical development stage for DMX-700 to treat chronic obstructive pulmonary disease. The company was founded in 2004 and is based in Fitzroy, Australia.